Direct thrombin inhibitors (part 2 of 2).
Arora
Umesh K
UK
Department of Medicine/Cardiology, University of Texas HSC at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA. umeen2111@aol.com
Dhir
Meeney
M
D000208:Acute Disease; D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000628:therapy; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006490:Hemostatics / Q000037:antagonists & inhibitors*; D006493:Heparin / Q000627:therapeutic use; D024764:Hirudin Therapy; D006629:Hirudins; D006801:Humans; D009203:Myocardial Infarction / Q000628:therapy; D010446:Peptide Fragments / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D013917:Thrombin / Q000037:antagonists & inhibitors*
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006490:Hemostatics; D006629:Hirudins; D010446:Peptide Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011994:Recombinant Proteins; D006493:Heparin; D013917:Thrombin; C074619:bivalirudin